A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
← catalyst calendarNCT07775404 · readout in 608 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
351estimated
Sites
49
Countries
China, Hong Kong, Malaysia +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-20
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-28 | estimated | When the study began enrolling |
| Primary completion | 2028-04-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-20 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
Interventions
- Drug: Elecoglipron
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercent change from baseline to Week 52 in body weight
measured Week 52
Participants achieving at least 5% body weight loss at Week 52
measured Week 52
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed